Search Medical Condition
Please enter condition
Please choose location

Cluj Napoca, Romania Clinical Trials

A listing of Cluj Napoca, Romania clinical trials actively recruiting patients volunteers.

RESULTS

Found (107) clinical trials

A Multicenter Randomized 52 Week Treatment Double-blind Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 g and QMF149 150/320 g via Concept1) over two respective MF doses (MF 400 g and MF 800 g via Twisthaler (total daily dose)) in poorly controlled asthmatic patients as ...

Phase

0.0 miles

Learn More »

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

A double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (Dose 1 and Dose 2) of QAW039 compared with placebo over a 52-week treatment period in in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma). Efficacy will ...

Phase

0.0 miles

Learn More »

Global Multicentre Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients

This is a multicenter long-term (up to five years post-conversion), non-interventional registry in kidney transplant patients who have been converted from tacrolimus BD to Advagraf. Centers that are providing medical care for kidney transplant patients who may convert patients from tacrolimus BD to Advagraf will be identified and requested to ...

Phase N/A

0.0 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

0.0 miles

Learn More »

Study Of Diabetic Nephropathy With Atrasentan

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a ...

Phase

0.0 miles

Learn More »

PankoMab-GEX Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response after 2nd to 4th line of chemotherapy in patients with epithelial ovarian or fallopian tube or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in a previous line, while the response to the ...

Phase

0.0 miles

Learn More »

A Phase III of ADT + Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-na ve Prostate Cancer.

Eligible patients can be randomize in the trial after his consent form has been signed, and after all inclusion and non-inclusion criteria have been checked. The randomisation will result in the allocation of arm A (ADT +docetaxel), arm B (ADT +docetaxel +Abiraterone), arm C (ADT +docetaxel +radiotherapy) or arm D ...

Phase

0.0 miles

Learn More »

A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

To evaluate the overall safety and efficacy of TRV027 when administered in addition to standard of care (SOC) on mortality, morbidity, dyspnea, and length of stay in patients hospitalized with Acute Decompensated Heart Failure (ADHF).

Phase

0.0 miles

Learn More »

An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

This single-arm, open-label, multicentre extension study will provide continued Avastin [bevacizumab] therapy to patients with solid tumours who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the Avastin therapy. Patients will receive the same dose and regimen as used in the previous parent trial and ...

Phase

0.0 miles

Learn More »

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase ...

Phase

0.0 miles

Learn More »